You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC

Transforming the Treatment of Hypertrophic Cardiomyopathy: Key Updates on Sarcomere-Directed Therapies

  • Authors: Martin S. Maron, MD; Ahmad Masri, MD, MS; Carolyn Ho, MD; Christopher M. Kramer, MD
  • CME / ABIM MOC Released: 11/28/2022
  • THIS ACTIVITY HAS EXPIRED FOR CREDIT
  • Valid for credit through: 11/28/2023, 11:59 PM EST
Start Activity


Target Audience and Goal Statement

This activity is intended for cardiologists, primary care physicians, and surgeons.

The goal of this activity is for learners to be better able to recognize the latest advances in the treatment of HCM, including new data for myosin inhibition therapy and implications for patient care.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Role of new and emerging sarcomere-directed therapies in addressing the underlying pathophysiology of HCM
    • Latest clinical trial data on the use of sarcomere-directed therapies to treat HCM
    • Key differences between new and emerging sarcomere-directed therapies for the treatment of HCM
  • Have greater competence related to
    • Clinical use of cardiac myosin inhibition therapy in patients with HCM


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


Moderator

  • Martin S. Maron, MD

    Director of the Hypertrophic Cardiomyopathy Center
    Lahey Hospital & Medical Center
    Burlington, Massachusetts

    Disclosures

    Martin S. Maron, MD, has the following relevant financial relationships:
    Consultant or advisor for: Cytokinetics; Imbria
    Speaker or member of speakers bureau for: iRhythm
    Research funding from: iRhythm
    Contracted researcher for: Cytokinetics; Imbria; iRhythm
    Other: Steering Committee for Cytokinetics

Faculty

  • Ahmad Masri, MD, MS

    Assistant Professor of Medicine
    Oregon Health & Science University
    Director, Hypertrophic Cardiomyopathy Center
    Director, Cardiac Amyloidosis Program
    Portland, Oregon

    Disclosures

    Ahmad Masri, MD, MS, has the following relevant financial relationships:
    Consultant or advisor for: Attralus; BridgeBio Pharma; Bristol Myers Squibb; Cytokinetics; Ionis; Tenaya Therapeutics
    Research funding from: Akcea; Ionis; Pfizer, Inc.; Ultromics

  • Carolyn Ho, MD

    Associate Professor
    Harvard Medical School
    Cardiovascular Medicine
    Brigham and Women's Hospital
    Medical Director of the Cardiovascular Genetics Center
    Boston, Massachusetts

    Disclosures

    Carolyn Ho, MD, has the following relevant financial relationships:
    Consultant or advisor for: Biomarin/DiNAQOR; Bristol Myers Squibb; Cytokinetics
    Research funding from: Bristol Myers Squibb; Pfizer, Inc.

  • Christopher M. Kramer, MD

    Distinguished Professor of Cardiovascular Medicine
    George A. Beller MD/Lantheus Medical Imaging
    Charlottesville, Virginia

    Disclosures

    Christopher M. Kramer, MD, has the following relevant financial relationships:
    Consultant or advisor for: Bristol Myers Squibb; Cytokinetics; Lilly; Xencor
    Research funding from: Bristol Myers Squibb; Cytokinetics; Lilly

Editor

  • Joy P. Marko, MS, APN-C, CCMEP

    Senior Medical Education Director, Medscape, LLC

    Disclosures

    Joy P. Marko, MS, APN-C, CCMEP, has no relevant financial relationships.

Compliance Reviewer

  • Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

Medscape

Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

Transforming the Treatment of Hypertrophic Cardiomyopathy: Key Updates on Sarcomere-Directed Therapies

Authors: Martin S. Maron, MD; Ahmad Masri, MD, MS; Carolyn Ho, MD; Christopher M. Kramer, MDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC Released: 11/28/2022

Valid for credit through: 11/28/2023, 11:59 PM EST

processing....

Learning Feedback Questions

Please answer these questions to complement your learning experience.

  • Print